Biological Therapies or Apremilast in the Treatment of Psoriasis in Patients with a History of Hematologic Malignancy: Results from a Retrospective Study in 21 Patients

BACKGROUND: Few studies addressing the safety and efficacy of biological therapy (BT) or apremilast (APR) in patients with psoriasis with a history of hematologic malignancy (HM) exist. AIM: To describe the tolerance and efficacy of BT and APR in moderate-to-severe psoriasis in patients with a histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen-Sors, Raphaella, Fougerousse, Anne-Claire, Reguiai, Ziad, Maccari, Francois, Mahé, Emmanuel, Delaunay, Juliette, Roussel, Aude, de la Breteque, Maud Amy, Cottencin, Caroline, Bertolotti, Antoine, Kemp, Hélène, Chaby, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275167/
https://www.ncbi.nlm.nih.gov/pubmed/34267533
http://dx.doi.org/10.2147/CCID.S320098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275167/
https://www.ncbi.nlm.nih.gov/pubmed/34267533
http://dx.doi.org/10.2147/CCID.S320098

Ejemplares similares